March 18 (Reuters) - Sarepta Therapeutics SRPT.O said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for rare muscular dystrophy.
Shares of the company fell nearly 24% to $77.29 in premarket trading.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
((Sriparna.Roy@thomsonreuters.com))